|Bid||79.72 x 800|
|Ask||87.24 x 800|
|Day's Range||84.26 - 85.74|
|52 Week Range||71.90 - 106.27|
|PE Ratio (TTM)||19.12|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||1.52 (1.65%)|
|1y Target Est||102.87|
The FDA released a list of drugmakers it said are getting in the way of generic drug development. Stocks of pharmacy benefit managers and biotech companies still outperformed the market. The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president's blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.
Big Pharma and biotech stocks popped Friday after a drug-pricing speech from President Trump was consistent with views that he would offer "more rhetoric than reform."
WASHINGTON—Prescription-drug wholesalers that for years shipped hundreds of opioid pills per person to small towns in West Virginia mostly denied they were a cause of surging addiction as lawmakers grilled them on Tuesday. Most company executives told a House hearing that their companies’ actions didn’t fan the opioid epidemic in the state. Only one executive, Joseph Mastandrea, chairman of Miami-Luken Inc. said that his company had a “shared responsibility” for the opioid crisis.
and H.D. Smith Wholesale Drug Company told the House Committee on Energy and Commerce their companies did not contribute to the opioids epidemic. The five drug distribution companies were ordered to appear before the committee on Tuesday, May 8. Since last May the committee has been investigating the number of opioid pills that were shipped to West Virginia.
George Barrett, executive chairman and past CEO of Cardinal Health Inc., apologized before a Congressional committee investigating the role of drug distributors in sending millions of doses of opioids to questionable pharmacies, particularly two in rural West Virginia. Barrett explained today's procedures would have blocked the shipments.
President Donald Trump is expected to outline new policies to deliver on his pledge to bring prices down in a speech that could come this week. The need to bring down high drug prices may be one of the few health care issues that draw bipartisan support in Washington and on Main Street.
Assessing AmerisourceBergen Corporation’s (NYSE:ABC) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check to buildRead More...
Drug distributor AmerisourceBergen Corp posted a better-than-expected quarterly profit on Wednesday and said it expects its Memphis facility to be fully operational by fiscal 2019, sending its shares up 5 percent. The company has spent about $22 million since the beginning of the year to fix problems at the facility, Chief Financial Officer Tim Guttman said on a conference call, adding any income contribution this year is expected to be nominal. The Memphis plant was acquired as part of a 2015 buy of PharMEDium Healthcare Holdings and has remained closed since December following inspections by the U.S. Food and Drug Administration.
AmerisourceBergen Corp. shares rose 2.2% in premarket trade Wednesday after the company reported second-quarter profit and revenue beats. Adjusted earnings-per-share came to $1.94, above the FactSet consensus of $1.82. Revenue rose to $41.03 billion from $37.15 billion, above the FactSet consensus of $40.55 billion.
The Chesterbrook, Pennsylvania-based company said it had profit of $1.29 per share. Earnings, adjusted for one-time gains and costs, came to $1.94 per share. The results exceeded Wall Street expectations. ...
Drug distributor AmerisourceBergen Corp on Wednesday posted a 30 percent fall in second-quarter profit hurt by high operating expenses. Operating costs soared 22.6 percent to $774.3 million. Net income ...
AmerisourceBergen Corporation today reported that in its fiscal year 2018 second quarter ended March 31, 2018, revenue increased 10.5 percent to $41.0 billion. On the basis of U.S.
On Wednesday, AmerisourceBergen (NYSE: ABC ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Based on AmerisourceBergen ...
Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.
A veteran AmerisourceBergen executive is joining Parexel as the contract research organization’s chief commercial and strategy officer.
Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.
The AmerisourceBergen Foundation is taking a scientific approach to combatting the opioid crisis in North Carolina and a number of other hard-hit states.
News Amazon is backing away from selling drugs to hospitals is no surprise to Walgreens Boots Alliance or CVS Health, which both have had their doubts about the online retailer's entrance in pharmacy.
Shares of Cardinal Health, McKesson, AmerisourceBergen, Walgreens Boots Alliance and CVS Health all rose on the news.
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
At the Berkshire Hathaway annual shareholder meeting, Warren Buffett and Charlie Munger discuss health care and finding a better way to provide it.